[1] P.J. Horner, F.H. Gage, Regenerating the damaged central nervous system, Nature 407 (2000) 407:963–970.
[2] E,T. Stoeckli, Understanding axon guidance: are we nearly there yet?, Development 145 (2018) dev151415.
[3] A.B. Huber, A.L. Kolodkin, D.D. Ginty, et al., Signaling at the growth cone: ligand-receptor complexes and the control of axon growth and guidance. Annu. Rev. Neurosci. 26 (2003) 509–563.
[4] G. Van Meer, D.R. Voelker, G.W. Feigenson, Membrane lipids: where they are and how they behave, Nat. Rev. Mol. Cell Biol. 9 (2008) 112–124.
[5] T.J. Tracey, F.J. Steyn, E.J. Wolvetang, et al., Neuronal lipid metabolism: multiple pathways driving functional outcomes in health and disease, Front. Mol. Neurosci.11 (2018) 10.
[6] J.W. Choi, J. Chun, Lysophospholipids and their receptors in the central nervous system, Biochim. Biophys. Acta. 1813 (2013) 20–32.
[7] W.J. Van Blitterswijk, G. De Veer, J.H. Krol, et al., Comparative lipid analysis of purified plasma membranes and shed extracellular membrane vesicles from normal murine thymocytes and leukemic GRSL cells, Biochim. Biophys. Acta. 688 (1982) 495–504.
[8] K. Makide, H. Kitamura, Y. Sato, et al., Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol, Prostaglandins. Other Lipid Mediat. 89 (2009) 135–139.
[9] A. Nishina, H. Kimura, A. Sekiguchi, et al., Lysophosphatidylethanolamine in Grifola frondosa as a neurotrophic activator via activation of MAPK, J. Lipid Res. 47 (2006) 1434–1443.
[10] K.S. Park, H.Y. Lee, S.Y. Lee, et al., Lysophosphatidylethanolamine stimulates chemotactic migration and cellular invasion in SK-OV3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor, FEBS Lett. 581 (2007) 4411–4416.
[11] S.J, Park, K.P. Lee, D.S. Im, Action and signaling of lysophosphatidylethanolamine in MDA-MB-231 breast cancer cells, Biomol. Ther. (Seoul) 22 (2014) 129–135.
[12] A. Montaner, T.T. da Silva Santana, T. Schroeder, et al., Specific phospholipids regulate the acquisition of neuronal and astroglial identities in post-mitotic cells, Sci Rep. 8 (2018) 460.
[13] J.G. Villamil-Ortiz, A. Barrera-Ocampo, D. Piedrahita, et al., BACE1 RNAi restores the composition of phosphatidylethanolamine-derivates related to memory improvement in Aged 3xTg-AD mice, Front Cell. Neurosci. 10 (2016) 260.
[14] S. Guo, D. Zhou, M. Zhang, et al., Monitoring changes of docosahexaenoic acid-containing lipids during the recovery process of traumatic brain injury in rat using mass spectrometry imaging, Sci. Rep. 7 (2017) 5054.
[15] A.M. Sabogal-Guáqueta, J.G. Villamil-Ortiz, J.D. Arias-Londoño, et al., Inverse phosphatidylcholine/phosphatidylinositol levels as peripheral biomarkers and phosphatidylcholine/lysophosphatidylethanolamine-phosphatidylserine as hippocampal indicator of postischemic cognitive impairment in rats, Front. Neurosci. 12 (2018) 989.
[16] T. Uemura, T. Shiroshima, A. Maeda, et al, In situ screening for postsynaptic cell adhesion molecules during synapse formation, J Biochem. 162 (2017) 295–302.
[17] Wuhanqimuge, A. Itakura, Y. Matsuki, M. et al., Lysophosphatidylcholine enhances NGF-induced MAPK and Akt signals through the extracellular domain of TrkA in PC12 cells, FEBS Open Bio. 3 (2013) 243–251.
[18] B.V. Bassa, D.D. Roh, N.D. Vaziri, et al., Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLCgamma-1 and tyrosine kinase-Ras pathways, Am. J. Physiol. 277 (1999) F328–337.
[19] S.A. Bennison, S.M. Blazejewski, T.H. Smith, et al., Protein kinases: master regulators of neuritogenesis and therapeutic targets for axon regeneration, Cell. Mol. Life Sci. 77 (2020) 1511–1530.
[20] S.J. Park, K.P. Lee, S. Kang, et al., Lysophosphatidylethanolamine utilizes LPA1 and CD97 in MDA-MB-231 breast cancer cells, Cell Signal. 25 (2013) 2147–2154.
[21] J.M. Lee, S.J Park, D.S. Im, Lysophosphatidylethanolamine increases intracellular Ca2+ through LPA1 in PC-12 neuronal cell, Biochem. Biophys. Res. Commun. 461 (2015) 378–382.
[22] J.M. Lee, S.J. Park, D.S. Im, Calcium signaling of lysophosphatidylethanolamine through LPA1 in human SH-SY5Y neuroblastoma cells, Biomol Ther (Seoul). 25 (2017) 194–201.
[23] M. Gschwendt, S. Dieterich, J. Rennecke, et al., Inhibition of protein kinase C μ by various inhibitors. Differentiation from protein kinase c isoenzymes, FEBS Lett. 392 (1996) 77–80.
[24] S.F. Steinberg, Structural basis of protein kinase C isoform function, Physiol. Rev. 88 (2008) 1341–1378.
[25] J.P. Evenou, J. Wagner, G. Zenke, et al., The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation, J. Pharmacol. Exp. Ther. 330 (2009) 792–801.
[26] B. Hille, G protein-coupled mechanisms and nervous signaling, Neuron. 9 (1992) 187-195.
[27] X. Liu, J. Li, P. Zheng, et al., Plasma lipidomics reveals potential lipid markers of major depressive disorder, Anal. Bioanal. Chem. 408 (2016) 6497–6507.